NCT06778733View on ClinicalTrials.gov

Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

April 30, 2024

Conditions
Female Infertility
Interventions
DRUG

Clomiphane citrate

Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))

DRUG

recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)

"All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)"

Trial Locations (2)

Unknown

Aretaieion University Hospital, Athens

Aretaieion University Hospital, Athens

All Listed Sponsors
lead

University of Athens

OTHER

NCT06778733 - Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders | Biotech Hunter | Biotech Hunter